Drug targeting RNA modifications shows promise for treating neuroblastoma

Neuroblastoma is a common pediatric cancer that originates in developing nerve cells outside the brain. While increasingly intensive treatments have improved the survival of patients with high-risk neuroblastoma, currently more than 40% of patients do not survive. New research from the University of Chicago shows the potential for a promising new approach to treating neuroblastoma by targeting RNA modifications associated with the disease.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news